Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-27

AUTHORS

Stanley Cohen, Ahmed Samad, Elaine Karis, Bradley S. Stolshek, Mona Trivedi, Hao Zhang, Girish A. Aras, Greg Kricorian, James B. Chung

ABSTRACT

INTRODUCTION: Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous administration may affect compliance or hinder initiation of prescribed medications. To improve the patient experience, a new phosphate-free formulation of etanercept was evaluated for reduced ISP associated with administration. METHODS: This phase 3b, multicenter, randomized, double-blind, cross-over study compared the prior formulation of etanercept to a phosphate-free formulation. Etanercept-naïve adults with RA or PsA indicated for treatment with etanercept were eligible. Patients were randomized (1:1) to receive both etanercept formulations (50 mg) in one of two crossover sequences: prior formulation followed by phosphate-free formulation (sequence AB) or phosphate-free formulation followed by prior formulation (sequence BA) at visits 1 week apart. Patients self-reported ISP using a fit-for-purpose 100-mm visual analog scale within 30 s after injection. Safety outcomes included incidence of treatment-emergent adverse events. Mixed-effects analysis of variance model was used to assess ISP, with treatment, study period, sequence, and disease indication as fixed-effect covariates and patient-within-sequence as random effect. RESULTS: A total of 111 patients enrolled (56 sequence AB; 55 sequence BA). Mean ISP score for prior formulation was 23.1 mm and for phosphate-free formulation was 19.1 mm (mean difference - 4 mm; 95% confidence interval: - 8.0, 0.0; P = 0.048). Patients with the highest ISP scores from the prior formulation (by quartile cut points) had the largest reduction in pain with phosphate-free formulation. Injection site reactions were few in number and similar between formulations; no new safety signals were observed. CONCLUSIONS: The new phosphate-free formulation of etanercept had statistically significantly lower mean pain scores than the prior formulation, with largest pain reductions observed among patients who reported highest pain with the prior formulation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02986139. FUNDING: Amgen Inc, Thousand Oaks, CA USA. More... »

PAGES

1-10

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40744-019-0152-8

DOI

http://dx.doi.org/10.1007/s40744-019-0152-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113009358

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30915626


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Metroplex Clinical Research Center", 
          "id": "https://www.grid.ac/institutes/grid.477482.a", 
          "name": [
            "Metroplex Clinical Research Center, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Stanley", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "US Medical, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Samad", 
        "givenName": "Ahmed", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "US Medical, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Karis", 
        "givenName": "Elaine", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "US Medical, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stolshek", 
        "givenName": "Bradley S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "US Medical, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trivedi", 
        "givenName": "Mona", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Biostatistics, Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Hao", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Biostatistics, Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aras", 
        "givenName": "Girish A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "US Medical, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kricorian", 
        "givenName": "Greg", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "US Medical, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "James B.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1136/emj.18.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001675476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd004525.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010351212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/ajem.2002.33778", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011813531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2015-208337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022767391"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.39480", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023015756"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3899/jrheum.100698", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024970950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1742-7843.2006.pto_271.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028718632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1742-7843.2006.pto_271.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028718632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1213/00000539-199802000-00030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037405901"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1213/00000539-199802000-00030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037405901"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ppa.s70834", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048181124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1592/phco.22.13.1105.33510", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052344509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077186306", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077419947", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077441453", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078964957", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082444216", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-210713", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084224205"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.xphs.2017.05.030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085722535"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1090618306", 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12016-017-8630-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090903301", 
          "https://doi.org/10.1007/s12016-017-8630-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41598-017-10110-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091313445", 
          "https://doi.org/10.1038/s41598-017-10110-w"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41598-017-10110-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091313445", 
          "https://doi.org/10.1038/s41598-017-10110-w"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.aaf9166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091396405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1932296817735121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092131553"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1932296817735121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092131553"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-27", 
    "datePublishedReg": "2019-03-27", 
    "description": "INTRODUCTION: Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous administration may affect compliance or hinder initiation of prescribed medications. To improve the patient experience, a new phosphate-free formulation of etanercept was evaluated for reduced ISP associated with administration.\nMETHODS: This phase 3b, multicenter, randomized, double-blind, cross-over study compared the prior formulation of etanercept to a phosphate-free formulation. Etanercept-na\u00efve adults with RA or PsA indicated for treatment with etanercept were eligible. Patients were randomized (1:1) to receive both etanercept formulations (50\u00a0mg) in one of two crossover sequences: prior formulation followed by phosphate-free formulation (sequence AB) or phosphate-free formulation followed by prior formulation (sequence BA) at visits 1\u00a0week apart. Patients self-reported ISP using a fit-for-purpose 100-mm visual analog scale within 30\u00a0s after injection. Safety outcomes included incidence of treatment-emergent adverse events. Mixed-effects analysis of variance model was used to assess ISP, with treatment, study period, sequence, and disease indication as fixed-effect covariates and patient-within-sequence as random effect.\nRESULTS: A total of 111 patients enrolled (56 sequence AB; 55 sequence BA). Mean ISP score for prior formulation was 23.1\u00a0mm and for phosphate-free formulation was 19.1\u00a0mm (mean difference -\u20094\u00a0mm; 95% confidence interval: -\u20098.0, 0.0; P\u2009=\u20090.048). Patients with the highest ISP scores from the prior formulation (by quartile cut points) had the largest reduction in pain with phosphate-free formulation. Injection site reactions were few in number and similar between formulations; no new safety signals were observed.\nCONCLUSIONS: The new phosphate-free formulation of etanercept had statistically significantly lower mean pain scores than the prior formulation, with largest pain reductions observed among patients who reported highest pain with the prior formulation.\nTRIAL REGISTRATION: ClinicalTrials.gov: NCT02986139.\nFUNDING: Amgen Inc, Thousand Oaks, CA USA.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40744-019-0152-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1052957", 
        "issn": [
          "2198-6576", 
          "2198-6584"
        ], 
        "name": "Rheumatology and Therapy", 
        "type": "Periodical"
      }
    ], 
    "name": "Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial", 
    "pagination": "1-10", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "ac1435861049cdcd051ee62742066d518a49781883fa0f721ba5f4470ab2092d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30915626"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101674543"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40744-019-0152-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113009358"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40744-019-0152-8", 
      "https://app.dimensions.ai/details/publication/pub.1113009358"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130820_00000006.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40744-019-0152-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40744-019-0152-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40744-019-0152-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40744-019-0152-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40744-019-0152-8'


 

This table displays all metadata directly associated to this object as RDF triples.

176 TRIPLES      21 PREDICATES      48 URIs      18 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40744-019-0152-8 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N74ae3dee73fa4b8d9751df0899450d09
4 schema:citation sg:pub.10.1007/s12016-017-8630-7
5 sg:pub.10.1038/s41598-017-10110-w
6 https://app.dimensions.ai/details/publication/pub.1077186306
7 https://app.dimensions.ai/details/publication/pub.1077419947
8 https://app.dimensions.ai/details/publication/pub.1077441453
9 https://app.dimensions.ai/details/publication/pub.1078964957
10 https://app.dimensions.ai/details/publication/pub.1082444216
11 https://app.dimensions.ai/details/publication/pub.1090618306
12 https://doi.org/10.1002/14651858.cd004525.pub2
13 https://doi.org/10.1002/art.39480
14 https://doi.org/10.1016/j.xphs.2017.05.030
15 https://doi.org/10.1053/ajem.2002.33778
16 https://doi.org/10.1111/j.1742-7843.2006.pto_271.x
17 https://doi.org/10.1126/scitranslmed.aaf9166
18 https://doi.org/10.1136/annrheumdis-2015-208337
19 https://doi.org/10.1136/annrheumdis-2016-210713
20 https://doi.org/10.1136/emj.18.3.205
21 https://doi.org/10.1177/1932296817735121
22 https://doi.org/10.1213/00000539-199802000-00030
23 https://doi.org/10.1592/phco.22.13.1105.33510
24 https://doi.org/10.2147/ppa.s70834
25 https://doi.org/10.3899/jrheum.100698
26 schema:datePublished 2019-03-27
27 schema:datePublishedReg 2019-03-27
28 schema:description INTRODUCTION: Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous administration may affect compliance or hinder initiation of prescribed medications. To improve the patient experience, a new phosphate-free formulation of etanercept was evaluated for reduced ISP associated with administration. METHODS: This phase 3b, multicenter, randomized, double-blind, cross-over study compared the prior formulation of etanercept to a phosphate-free formulation. Etanercept-naïve adults with RA or PsA indicated for treatment with etanercept were eligible. Patients were randomized (1:1) to receive both etanercept formulations (50 mg) in one of two crossover sequences: prior formulation followed by phosphate-free formulation (sequence AB) or phosphate-free formulation followed by prior formulation (sequence BA) at visits 1 week apart. Patients self-reported ISP using a fit-for-purpose 100-mm visual analog scale within 30 s after injection. Safety outcomes included incidence of treatment-emergent adverse events. Mixed-effects analysis of variance model was used to assess ISP, with treatment, study period, sequence, and disease indication as fixed-effect covariates and patient-within-sequence as random effect. RESULTS: A total of 111 patients enrolled (56 sequence AB; 55 sequence BA). Mean ISP score for prior formulation was 23.1 mm and for phosphate-free formulation was 19.1 mm (mean difference - 4 mm; 95% confidence interval: - 8.0, 0.0; P = 0.048). Patients with the highest ISP scores from the prior formulation (by quartile cut points) had the largest reduction in pain with phosphate-free formulation. Injection site reactions were few in number and similar between formulations; no new safety signals were observed. CONCLUSIONS: The new phosphate-free formulation of etanercept had statistically significantly lower mean pain scores than the prior formulation, with largest pain reductions observed among patients who reported highest pain with the prior formulation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02986139. FUNDING: Amgen Inc, Thousand Oaks, CA USA.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf sg:journal.1052957
33 schema:name Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial
34 schema:pagination 1-10
35 schema:productId N21681f0b992c481abbf29373ab11ce05
36 N79a720aee9a648ba8e15c0b0c9700d64
37 N9e87775ea2bf4bc9b9c1152ec13db775
38 N9fae15d52a9f4a04ac93355b1b54c229
39 Nd0f2fbaceeaf4e61a2cb668bcdb6496c
40 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113009358
41 https://doi.org/10.1007/s40744-019-0152-8
42 schema:sdDatePublished 2019-04-11T13:58
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher Na3342c4719054dc28f6074e10725d3e5
45 schema:url https://link.springer.com/10.1007%2Fs40744-019-0152-8
46 sgo:license sg:explorer/license/
47 sgo:sdDataset articles
48 rdf:type schema:ScholarlyArticle
49 N20b215bb8be647b99e54f82a517c689d schema:affiliation https://www.grid.ac/institutes/grid.417886.4
50 schema:familyName Aras
51 schema:givenName Girish A.
52 rdf:type schema:Person
53 N21681f0b992c481abbf29373ab11ce05 schema:name doi
54 schema:value 10.1007/s40744-019-0152-8
55 rdf:type schema:PropertyValue
56 N2610238aaf984040888296aa493ded97 rdf:first N54fdbf17058747fe9fa782f526c8d890
57 rdf:rest N8dc3d0e8cb694339a1106cb68a833ec3
58 N38f0dd9c04774df89a6d2a9052e02dbf rdf:first N83cf330534be41ab89f82bfe7f253cb9
59 rdf:rest Nbd420b4486d942759b0fcf858c6fdff8
60 N3e1828555573469f90ba839c6edd6b3e schema:affiliation https://www.grid.ac/institutes/grid.477482.a
61 schema:familyName Cohen
62 schema:givenName Stanley
63 rdf:type schema:Person
64 N54fdbf17058747fe9fa782f526c8d890 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
65 schema:familyName Samad
66 schema:givenName Ahmed
67 rdf:type schema:Person
68 N59559dbf5d084aecb128791842b6b300 rdf:first N65ad035b9dd6408388886e7b512b79fd
69 rdf:rest Nf1b5109e73994299a7f5c3067ab45edb
70 N65ad035b9dd6408388886e7b512b79fd schema:affiliation https://www.grid.ac/institutes/grid.417886.4
71 schema:familyName Zhang
72 schema:givenName Hao
73 rdf:type schema:Person
74 N72386425186a443e9a3c56a232fc00a1 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
75 schema:familyName Trivedi
76 schema:givenName Mona
77 rdf:type schema:Person
78 N74ae3dee73fa4b8d9751df0899450d09 rdf:first N3e1828555573469f90ba839c6edd6b3e
79 rdf:rest N2610238aaf984040888296aa493ded97
80 N79a720aee9a648ba8e15c0b0c9700d64 schema:name dimensions_id
81 schema:value pub.1113009358
82 rdf:type schema:PropertyValue
83 N80afba082a2e4f34aefec9e42cf6834c rdf:first N72386425186a443e9a3c56a232fc00a1
84 rdf:rest N59559dbf5d084aecb128791842b6b300
85 N83cf330534be41ab89f82bfe7f253cb9 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
86 schema:familyName Kricorian
87 schema:givenName Greg
88 rdf:type schema:Person
89 N8dc3d0e8cb694339a1106cb68a833ec3 rdf:first Nfa941ecffd9343239f4d962e0f0a5208
90 rdf:rest Na47af5ec365a491482205ac720c98802
91 N9e87775ea2bf4bc9b9c1152ec13db775 schema:name nlm_unique_id
92 schema:value 101674543
93 rdf:type schema:PropertyValue
94 N9fae15d52a9f4a04ac93355b1b54c229 schema:name pubmed_id
95 schema:value 30915626
96 rdf:type schema:PropertyValue
97 Na3342c4719054dc28f6074e10725d3e5 schema:name Springer Nature - SN SciGraph project
98 rdf:type schema:Organization
99 Na47af5ec365a491482205ac720c98802 rdf:first Nf30edcf16b7a45da80ae078ac56bfeff
100 rdf:rest N80afba082a2e4f34aefec9e42cf6834c
101 Nbd420b4486d942759b0fcf858c6fdff8 rdf:first Nde05529be66b46bc80a95f767162ac33
102 rdf:rest rdf:nil
103 Nd0f2fbaceeaf4e61a2cb668bcdb6496c schema:name readcube_id
104 schema:value ac1435861049cdcd051ee62742066d518a49781883fa0f721ba5f4470ab2092d
105 rdf:type schema:PropertyValue
106 Nde05529be66b46bc80a95f767162ac33 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
107 schema:familyName Chung
108 schema:givenName James B.
109 rdf:type schema:Person
110 Nf1b5109e73994299a7f5c3067ab45edb rdf:first N20b215bb8be647b99e54f82a517c689d
111 rdf:rest N38f0dd9c04774df89a6d2a9052e02dbf
112 Nf30edcf16b7a45da80ae078ac56bfeff schema:affiliation https://www.grid.ac/institutes/grid.417886.4
113 schema:familyName Stolshek
114 schema:givenName Bradley S.
115 rdf:type schema:Person
116 Nfa941ecffd9343239f4d962e0f0a5208 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
117 schema:familyName Karis
118 schema:givenName Elaine
119 rdf:type schema:Person
120 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
121 schema:name Medical and Health Sciences
122 rdf:type schema:DefinedTerm
123 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
124 schema:name Clinical Sciences
125 rdf:type schema:DefinedTerm
126 sg:journal.1052957 schema:issn 2198-6576
127 2198-6584
128 schema:name Rheumatology and Therapy
129 rdf:type schema:Periodical
130 sg:pub.10.1007/s12016-017-8630-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090903301
131 https://doi.org/10.1007/s12016-017-8630-7
132 rdf:type schema:CreativeWork
133 sg:pub.10.1038/s41598-017-10110-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1091313445
134 https://doi.org/10.1038/s41598-017-10110-w
135 rdf:type schema:CreativeWork
136 https://app.dimensions.ai/details/publication/pub.1077186306 schema:CreativeWork
137 https://app.dimensions.ai/details/publication/pub.1077419947 schema:CreativeWork
138 https://app.dimensions.ai/details/publication/pub.1077441453 schema:CreativeWork
139 https://app.dimensions.ai/details/publication/pub.1078964957 schema:CreativeWork
140 https://app.dimensions.ai/details/publication/pub.1082444216 schema:CreativeWork
141 https://app.dimensions.ai/details/publication/pub.1090618306 schema:CreativeWork
142 https://doi.org/10.1002/14651858.cd004525.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010351212
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1002/art.39480 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023015756
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1016/j.xphs.2017.05.030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085722535
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1053/ajem.2002.33778 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011813531
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1111/j.1742-7843.2006.pto_271.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1028718632
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1126/scitranslmed.aaf9166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091396405
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1136/annrheumdis-2015-208337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022767391
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1136/annrheumdis-2016-210713 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084224205
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1136/emj.18.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001675476
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1177/1932296817735121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092131553
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1213/00000539-199802000-00030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037405901
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1592/phco.22.13.1105.33510 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052344509
165 rdf:type schema:CreativeWork
166 https://doi.org/10.2147/ppa.s70834 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048181124
167 rdf:type schema:CreativeWork
168 https://doi.org/10.3899/jrheum.100698 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024970950
169 rdf:type schema:CreativeWork
170 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
171 schema:name Biostatistics, Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA
172 US Medical, Amgen Inc., Thousand Oaks, CA, USA
173 rdf:type schema:Organization
174 https://www.grid.ac/institutes/grid.477482.a schema:alternateName Metroplex Clinical Research Center
175 schema:name Metroplex Clinical Research Center, Dallas, TX, USA
176 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...